Imaging addiction with PET: Is insight in sight?

Drug Discovery Today

Volumn 10, Issue 8, 2005, Pages 547-562

  Schiffer, Wynne K ^a,b   Lee, Dianne E ^b   Brodie, Jonathan D ^c   Dewey, Stephen L ^a,b  

^a Stony Brook University   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLSPIPERONE C 11; ALCOHOL C 11; AMPHETAMINE C 11; CARFENTANIL C 11; CLORGYLINE C 11; COCAINE C 11; DOPA C 11; FLUMAZENIL C 11; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLSPIPERONE C 11; METHAMPHETAMINE C 11; NICOTINE C 11; PHENCYCLIDINE C 11; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; SELEGILINE C 11; TOLUENE C 11; UNCLASSIFIED DRUG;

ADDICTION; BRAIN CELL; COMPUTER ASSISTED TOMOGRAPHY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG RECEPTOR BINDING; DRUG TARGETING; HEALTH BEHAVIOR; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; IN VIVO STUDY; INTERMETHOD COMPARISON; MEDICAL INFORMATION; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NEUROIMAGING; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WITHDRAWAL SYNDROME;

ANIMALS; FORECASTING; HUMANS; POSITRON-EMISSION TOMOGRAPHY; SUBSTANCE-RELATED DISORDERS; TERMINOLOGY;

EID: 17444384899     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03412-4     Document Type: Review

References (115)

1. O'Brien, C. and Fischman, M.W. (2002) Substance Use Disorders. In Neuropsychopharmacology: The Fifth Generation of Progress (Davis, K.L. et al., eds), p. 1355, Lippincott Williams and Wilkins
2. Nyback H., et al. PET studies of the uptake of (S)- and (R)-[11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo. Psychopharmacology (Berl.). 115:1994;31-36
3. Fowler J.S., et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse. 4:1989;371-377
4. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog. Neurobiol. 56:1998;613-672
5. Weiss F., et al. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann N Y Acad Sci. 937:2001;1-26
6. Roberts D.C., et al. On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. Pharmacol. Biochem. Behav. 6:1977;615-620
7. Zito K.A., et al. Disruption of cocaine and heroin self-administration following kainic acid lesions of the nucleus accumbens. Pharmacol. Biochem. Behav. 23:1985;1029-1036
8. Koob G.F. Hedonic valence, dopamine and motivation. Molecular Psychiatry. 1:1996;186-189
9. Abi-Dargham A., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 97:2000;8104-8109
10. Volkow N.D., et al. Imaging studies of cocaine in the human brain and studies of the cocaine addict. Ann. N. Y. Acad. Sci. 820:1997;41-54
11. Volkow N.D., et al. Cocaine uptake is decreased in the brain of detoxified cocaine abusers. Neuropsychopharmacology. 14:1996;159-168
12. Di Chiara G., Imperato A. Drugs of abuse preferentially stimulate dopamine release in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U. S. A. 85:1988;5274-5278
13. Balster R.L., Bigelow G.E. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 70:(Suppl. 3):2003;S13-S40
14. Schiffer W.K., et al. Stereoselective inhibition of dopaminergic activity by gamma vinyl-GABA following a nicotine or cocaine challenge: a PET/microdialysis study. Life Sci. 66:2000;PL169-PL173
15. Cumming P., et al. Effects of acute nicotine on hemodynamics and binding of [11C]raclopride to dopamine D2,3 receptors in pig brain. Neuroimage. 19:2003;1127-1136
16. Brodie J.D., et al. Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse. 50:2003;261-265
17. Smith G.S., et al. Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects. Am. J. Psychiatry. 154:1997;490-496
18. Dewey S.L., et al. GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. J. Neurosci. 12:1992;3773-3780
19. Smith G.S., et al. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology. 18:1998;18-25
20. Dewey S.L., et al. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc. Natl. Acad. Sci. U. S. A. 90:1993;11816-11820
21. Lingford-Hughes A.R., et al. Addiction. Br. Med. Bull. 65:2003;209-222
22. Yu R.C., et al. Genetic toxicity of cocaine. Carcinogenesis. 20:1999;1193-1199
23. Hayase T., et al. Microarray profile analysis of toxic cocaine-induced alterations in the expression of mouse brain gene sequences: a possible 'protective' effect of buprenorphine. J. Appl. Toxicol. 24:2004;15-20
24. O'Brien C.P. A range of research-based pharmacotherapies for addiction. Science. 278:1997;66-70
25. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Research Reviews. 18:1993;75-113
26. Wolf M.E. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog. Neurobiol. 54:1998;679-720
27. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308
28. Beardsley P.M., et al. The self-administration of MK-801 can depend upon drug-reinforcement history, and its discriminative stimulus properties are phencyclidine-like in rhesus monkeys. J. Pharmacol. Exp. Ther. 252:1990;953-959
29. Collins E.D., et al. Amantadine does not modulate reinforcing, subjective, or cardiovascular effects of cocaine in humans. Pharmacol. Biochem. Behav. 76:2003;401-407
30. Schiffer W.K., et al. Positron emission tomography studies of potential mechanisms underlying phencyclidine-induced alterations in striatal dopamine. Neuropsychopharmacology. 28:2003;2192-2198
31. Kosten T.R. The pharmacotherapy of relapse prevention using anticonvulsants. Am. J. Addict. 7:1998;205-209
32. Gasior M., et al. Preclinical evaluation of newly approved and potential antiepileptic drugs against cocaine-induced seizures. J. Pharmacol. Exp. Ther. 290:1999;1148-1156
33. Jung M.J., et al. gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J. Neurochem. 29:1977;797-802
34. Schiffer W.K., et al. Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine. Psychopharmacology (Berl.). 168:2003;339-343
35. Jolkkonen J., et al. Acute effects of gamma-vinyl GABA on the GABAergic system in rats as studied by microdialysis. Eur. J. Pharmacol. 229:1992;269-272
36. Ben-Menachem E., et al. Effect of long-term vigabatrin therapy on selected neurotransmitter concentrations in cerebrospinal fluid. J. Child Neurol. (Suppl 2):1991;S11-S16
37. Gerasimov M.R., et al. Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol- induced increases in nucleus accumbens dopamine. Synapse. 34:1999;11-19
38. Dewey S.L., et al. A novel strategy for the treatment of cocaine addiction. Synapse. 30:1998;119-129
39. Dewey S.L., et al. A pharmacologic strategy for the treatment of nicotine addiction. Synapse. 31:1999;76-86
40. Gardner E.L., et al. Gamma-vinyl GABA, an irreversible inhibitor of GABA transaminase, alters the acquisition and expression of cocaine-induced sensitization in male rats. Synapse. 46:2002;240-250
41. Kushner S.A., et al. Gamma-vinyl GABA attenuates cocaine-induced lowering of brain stimulation reward thresholds. Psychopharmacology (Berl.). 133:1997;383-388
42. Kushner S.A., et al. Comparison of the effects of vigabatrin on cocaine self-administration and food reinforcement. Society for Neuroscience Abstracts. 23:1997;1942
43. Stromberg M.F., et al. The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat. Pharmacol. Biochem. Behav. 68:2001;291-299
44. Paul M., et al. Gamma-vinyl GABA (GVG) blocks expression of the conditioned place preference response to heroin in rats. Synapse. 41:2001;219-220
45. Lee D.E., et al. Gamma-vinyl GABA (vigabatrin) blocks the expression of toluene-induced conditioned place preference (CPP). Synapse. 54:2004;183-185
46. Bialer M., et al. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 43:2001;11-58
47. Eke T., et al. Severe persistent visual field constriction associated with vigabatrin. BMJ. 314:1997;180-181
48. Beran R.G., et al. Predictability of visual field defects in patients exposed to GABAergic agants, vigabatrin or tiagabine. Neurology. 52:(Suppl. 2):1998;A249
49. Kalviainen R., et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology. 53:1999;922-926
50. Manuchehri K., et al. A controlled study of vigabatrin and visual abnormalities. Br. J. Ophthalmol. 84:2000;499-505
51. Manuchehri K. Visual field defect associated with vigabatrin. Method of estimating prevalence was inappropriate. BMJ. 320:2000;1403-1404
52. Brodie J.D., et al. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse. 55:2005;122-125
53. Fechtner, R.D. and Khouri, A.S. Visual field unaffected by short-term treatment with vigabatrin for cocaine and methamphetamine abuse. Invest. Ophthalmol. Vis. Sci.
54. Petroff O.A., Rothman D.L. Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin. Mol. Neurobiol. 16:1998;97-121
55. Richerson G.B., Wu Y. Dynamic equilibrium of neurotransmitter transporters: not just for reuptake anymore. J. Neurophysiol. 90:2003;1363-1374
56. Abe M., Matsuda M. On the existence of two GABA pools associated with newly synthesized GABA and with newly taken up GABA in nerve terminals. Neurochem. Res. 8:1983;563-573
57. Cooper J.R., et al. The Biochemical Basis of Neuropharmacology. 2003;Oxford University Press
58. Attwell D., et al. Nonvesicular release of neurotransmitter. Neuron. 11:1993;401-407
59. Wu Y., et al. GABA transaminase inhibition induces spontaneous and enhances depolarization-evoked GABA efflux via reversal of the GABA transporter. J. Neurosci. 21:2001;2630-2639
60. Spanaki M.V., et al. The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism. Neurology. 53:1999;1518-1522
61. Swerdlow N.R., et al. The neural substrates for the motor-activating properties of psychostimulants: a review of recent findings. Pharmacol. Biochem. Behav. 25:1986;233-248
62. Roberts D.C., Brebner K. GABA modulation of cocaine self-administration. Ann. N. Y. Acad. Sci. 909:2000;145-158
63. Ling W., et al. Baclofen as a cocaine anti-craving medication: a preliminary clinical study. Neuropsychopharmacology. 18:1998;403-404
64. Munzar P., et al. Failure of baclofen to modulate discriminative-stimulus effects of cocaine or methamphetamine in rats. Eur. J. Pharmacol. 408:2000;169-174
65. Agmo A., Giordano M. The locomotor-reducing effects of GABAergic drugs do not depend on the GABAA receptor. Psychopharmacology (Berl.). 87:1985;51-54
66. Meltzer P.C., et al. Design and synthesis of an irreversible dopamine-sparing cocaine antagonist. Bioorg. Med. Chem. 10:2002;3583-3591
67. Castner S.A., et al. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science. 287:2000;2020-2022
68. Pilla M., et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature. 400:1999;371-375
69. Haney M., Kosten T.R. Therapeutic vaccines for substance dependence. Expert Rev. Vaccines. 3:2004;11-18
70. Kosten T.R., et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine. 20:2002;1196-1204
71. Scanziani M., et al. Use-dependent increases in glutamate concentration activate presynaptic metabotropic glutamate receptors. Nature. 385:1997;630-634
72. Kreek M.J., et al. Pharmacotherapy of addictions. Nat. Rev. Drug Discov. 1:2002;710-726
73. Vocci F., et al. Overview: medications development for the treatment of drug abuse. NIDA Res. Monogr. 149:1995;4-15
74. Pouletty P. Drug addictions: towards socially accepted and medically treatable diseases. Nat. Rev. Drug Discov. 1:2002;731-736
75. Vollenweider F.X., et al. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man-a PET study with [11C]raclopride. Neuropsychopharmacology. 20:1999;424-433
76. Seeman P., et al. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain. Synapse. 3:1989;96-97
77. Dewey S.L., et al. Amphetamine induced decreases in (18F)-N- methylspiroperidol binding in the baboon brain using positron emission tomography (PET). Synapse. 7:1991;324-327
78. Volkow N.D., et al. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J. Psychopharmacol. 13:1999;337-345
79. London E.D., et al. Cocaine-induced reduction of glucose utilization in human brain. A study using positron emission tomography and [fluorine 18]-fluorodeoxyglucose. Arch. Gen. Psychiatry. 47:1990;567-574
80. Schlaepfer T.E., et al. PET study of competition between intravenous cocaine and [11C]raclopride at dopamine receptors in human subjects. Am. J. Psychiatry. 154:1997;1209-1213
81. Wu J.C., et al. Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal. Neuropsychopharmacology. 17:1997;402-409
82. Zubieta J.K., et al. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat. Med. 2:1996;1225-1229
83. Muzic R.F. Jr, et al. PET quantification of specific binding of carbon-11-nicotine in human brain. J. Nucl. Med. 39:1998;2048-2054
84. London E.D. Effects of nicotine on cerebral metabolism. Ciba Found. Symp. 152:1990;131-140
85. Gulyas B., et al. Cerebral uptake of [ethyl-11C]vinpocetine and 1-[11C]ethanol in cynomolgous monkeys: a comparative preclinical PET study. Nucl. Med. Biol. 29:2002;753-759
86. Wang G.J., et al. Regional brain metabolism during alcohol intoxication. Alcohol. Clin. Exp. Res. 24:2000;822-829
87. Boileau I., et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse. 49:2003;226-231
88. Nakamura H., et al. Effects of haloperidol and cocaine pretreatments on brain distribution and kinetics of [11C]methamphetamine in methamphetamine sensitized dog: application of PET to drug pharmacokinetic study. Nucl. Med. Biol. 24:1997;165-169
89. Wang G.J., et al. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am. J. Psychiatry. 161:2004;242-248
90. Tsukada H., et al. Comparative effects of methamphetamine and nicotine on the striatal [(11)C]raclopride binding in unanesthetized monkeys. Synapse. 45:2002;207-212
91. Volkow N.D., et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry. 158:2001;377-382
92. Shiue C.Y., et al. Comparative PET studies of the distribution of (-)-3,4-methylenedioxy-N-[11C]methamphetamine and (-)-[11C]methamphetamine in a monkey brain. Nucl. Med. Biol. 22:1995;321-324
93. Vollenweider F.X., et al. Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). Psychiatry Res. 83:1998;149-162
94. Drevets W.C., et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol. Psychiatry. 49:2001;81-96
95. Charalambous A., et al. PET studies in the primate brain and biodistribution in mice using (-)- 5′-18F-delta 8-THC. Pharmacol. Biochem. Behav. 40:1991;503-507
96. Mathew R.J., et al. Time course of tetrahydrocannabinol-induced changes in regional cerebral blood flow measured with positron emission tomography. Psychiatry Res. 116:2002;173-185
97. Volkow N.D., et al. Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Res. 67:1996;29-38
98. Gardner E.L., Lowinson J.H. Marijuana's interaction with brain reward systems: update 1991. Pharmacol. Biochem. Behav. 40:1991;571-580
99. Biegon A., et al. Dynamic changes in N-methyl-D-aspartate receptors after closed head injury in mice: Implications for treatment of neurological and cognitive deficits. Proc. Natl. Acad. Sci. U. S. A. 101:2004;5117-5122
100. Hammers A., et al. Correlation of memory function with binding of [C-11]CNS 5161, a novel putative NMDA ion channel PET ligand. In NeuroReceptor Mapping (Vol. O28). NeuroImage. 2004
101. Wu J.C., et al. Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia. Yakubutsu Seishin Kodo. 11:1991;47-48
102. Aalto S., et al. Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology (Berl.). 164:2002;401-406
103. Gerasimov M.R., et al. Study of brain uptake and biodistribution of C-11 toluene in non-human primates and mice. Life Sci. 70:2002;2811-2828
104. Hageman G., et al. Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure. J. Neurol. 246:1999;198-206
105. Edling C., et al. Do organic solvents induce changes in the dopaminergic system? Positron emission tomography studies of occupationally exposed subjects. Int. Arch. Occup. Environ. Health. 70:1997;180-186
106. Melichar J.K., et al. Using [11C]-Diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J. Pharmacol. Exp. Ther. 312:2004;309-315
107. London E.D., et al. Morphine-induced metabolic changes in human brain. Studies with positron emission tomography and [fluorine 18]fluorodeoxyglucose. Arch. Gen. Psychiatry. 47:1990;73-81
108. Hagelberg N., et al. Mu-receptor agonism with alfentanil increases striatal dopamine D2 receptor binding in man. Synapse. 45:2002;25-30
109. Smith G.S. Opiate modulation of striatal dopamine release measured with positron emission tomography (PET) and 11C-raclopride. Soc. Neurosci. Abstr. 19:1993;302
110. Wang G.J., et al. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology. 16:1997;174-182
111. Holthoff V.A., et al. Differentiation of radioligand delivery and binding in the brain: validation of a two-compartment model for [11C]flumazenil. J. Cereb. Blood Flow Metab. 11:1991;745-752
112. Abadie P., et al. Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography. Eur. J. Pharmacol. 295:1996;35-44
113. Volkow N.D., et al. Depression of thalamic metabolism by lorazepam is associated with sleepiness. Neuropsychopharmacology. 12:1995;123-132
114. Matthew E., et al. Benzodiazepine receptors mediate regional blood flow changes in the living human brain. Proc. Natl. Acad. Sci. U. S. A. 92:1995;2775-2779
115. Hietala J., et al. Effects of lorazepam administration on striatal dopamine D2 receptor binding characteristics in man-a positron emission tomography study. Psychopharmacology (Berl.). 132:1997;361-365